- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01356173
Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
November 1, 2016 updated by: Genentech, Inc.
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically documented, locally advanced or metastatic solid malignancy or NHL without leukemic phase that has progressed or failed to respond to at least one prior regimen and/or are not candidates for regimens known to provide clinical benefit
- Evaluable or measurable disease per RECIST v1.1 or IWG response criteria for patients with NHL and/or the following: prostate cancer patients with non-measurable disease are eligible if they have two rising prostate-specific antigen (PSA) levels >= 5 ng/mL measured >= 2 weeks apart that meet the PSA, and Working Group criteria for progression prior to initiation of study treatment, and ovarian cancer patients with non-measurable disease are eligible if they have two rising CA-125 levels greater than the ULN >= 2 weeks apart prior to initiation of study treatment.
- ECOG performance status of 0 or 1 at screening
- Life expectancy of >= 12 weeks
- Adequate hematologic and organ function within 14 days prior to initiation of study treatment
- Documented willingness to use an effective means of contraception for both men and women while participating in the study and for 90 days after the last dose of GDC-0349
- Willingness to provide archival tumor tissue
Exclusion Criteria:
- Leptomeningeal disease as the only manifestation of the current malignancy
- History of Type 1 or 2 diabetes requiring daily medication
- Known untreated central nervous system (CNS) malignancies or treated brain metastases that are not radiographically stable for >= 3 months prior to initiation of study treatment
- Active congestive heart failure or ventricular arrhythmia requiring medication
- Uncontrolled ascites requiring weekly large-volume paracentesis for 3 consecutive weeks prior to initiation of study treatment
- Active infection requiring intravenous (IV) antibiotics
- Patients requiring any daily supplemental oxygen
- Uncontrolled hypomagnesemia or hypokalemia
- Any condition requiring anti-coagulants such as warfarin, heparin, or anti-thrombotics. Prophylactic anti-coagulation and/or local application of thrombolytic agents for catheter patency may be allowed for patients with normal INR and with prior approval from the Medical Monitor
- Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
- Known human immunodeficiency virus (HIV) infection
- Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications
- Significant traumatic injury within 3 weeks prior to initiation of GDC-0349
- Major surgical procedure within 4 weeks prior to initiation of GDC-0349
- Treatment with chemotherapy, hormonal therapy (except GnRH agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, or radiation therapy (except palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment. Kinase inhibitors, approved by national regulatory authorities, may be used up to 2 weeks prior to initiation of GDC-0349, provided that any drug-related toxicity has completely resolved and prior approval is obtained from the Medical Monitor.
- Palliative radiation to bony metastases within 2 weeks prior to initiation of GDC-0349
- Treatment with an investigational agent within 4 weeks prior to initiation of GDC-0349
- Unresolved toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy
- Pregnancy or lactation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
|
Oral escalating dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of dose limiting toxicities (DLTs) by NCI CTCAE v4.0 grade and associated dose of GDC-0349
Time Frame: Up to 30 days
|
Up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events by NCI CTCAE v4.0 grade and associated dose of GDC-0349
Time Frame: Up to 2 years
|
Up to 2 years
|
Incidence of Grade 3 and 4 abnormalities in safety related laboratory parameters and associated dose of GDC-0349
Time Frame: Up to 30 days
|
Up to 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
May 17, 2011
First Submitted That Met QC Criteria
May 18, 2011
First Posted (Estimate)
May 19, 2011
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MKI4956g
- MP00807 (Other Identifier: Hoffmann-La Roche)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma, Solid Tumor
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Antengene Biologics LimitedRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Mature B-cell Non-Hodgkin LymphomaUnited States, Australia
-
Changchun GeneScience Pharmaceutical Co., Ltd.TerminatedSolid Tumor | Non-Hodgkin LymphomaChina
-
Adagene (Suzhou) LimitedCompletedSolid Tumor | Non-Hodgkin LymphomaChina
-
Adagene (Suzhou) LimitedTerminatedSolid Tumor | Non Hodgkin LymphomaChina
-
Antengene Therapeutics LimitedTerminatedSolid Tumor, Non-Hodgkin's LymphomaChina, Taiwan
-
BayerCompletedNon-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Advanced Solid TumorUnited States, Canada, China, Japan, Singapore, United Kingdom, Switzerland
-
Genentech, Inc.CompletedNon-Hodgkin's Lymphoma, Solid CancersUnited States, United Kingdom
-
Genentech, Inc.CompletedNon-Hodgkin's Lymphoma, Solid CancersUnited Kingdom
Clinical Trials on GDC-0349
-
Novo Nordisk A/SWithdrawnObesity | Metabolism and Nutrition Disorder
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.CompletedHealthy VolunteerUnited States
-
Genentech, Inc.CompletedHealthy VolunteersUnited Kingdom
-
Genentech, Inc.TerminatedLupus Erythematosus, SystemicUnited States, Korea, Republic of, Spain, Taiwan, Bulgaria, Colombia, Brazil, Argentina, Mexico, Chile, United Kingdom
-
Genentech, Inc.Terminated
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.CompletedHealthy VolunteersUnited States